Tofogliflozin (CAS: 903565-80-8) is a synthetic specialty chemical compound with the molecular formula C₂₂H₂₅ClF₄N₂O₅S, primarily used as an active pharmaceutical ingredient (API) in the treatment of type 2 diabetes mellitus. It functions as a sodium-glucose co-transporter 2 (SGLT2) inhibitor, which helps to lower blood glucose levels by preventing the reabsorption of glucose in the kidneys. This leads to increased excretion of glucose through urine, thereby reducing overall blood sugar levels. It is often prescribed when other diabetes medications have not provided adequate control. Additionally, Tofogliflozin has shown potential benefits in reducing cardiovascular risks, which is particularly important for diabetic patients who are at higher risk for heart-related complications. It is typically administered orally and is part of a comprehensive diabetes management plan that includes diet, exercise, and regular monitoring of blood glucose levels. As a reagent, it is supplied at high purity (e.g., 98%) for pharmaceutical research, synthesis, or analytical purposes.